Name |
|
AMR research |
|
Linda Oyama |
Discovery and development of antimicrobial peptides for MDR bacteria and fungi indicated in infections in the human- veterinary interface as well as system-level understanding of AMR burden and transmission in earth’s microbiomes (human-animal-plant-environment) and implications for One Health. |
|
|
Ryan Donnelly |
Bypassing the gut to circumvent development of resistance, photodynamic antimicrobial chemotherapy |
|
|
Ilias Kyriazakis |
Development of systems that minimise the occurrence of AMR, including modelling of treatment effects on the rate of development of AMR, such as the application of targeted selective treatments. Detection of frequency of AMR genes. |
|
|
Deirdre Gilpin |
AMR in chronic lung and urinary tract infection, detection of AMR in Wastewater |
|
|
Guanbo Wang |
The mechanism of "heteroresistance", which is a phenomenon in which a susceptible bacteria isolate harbours a resistant subpopulation that can grow in the presence of an antibiotic and cause treatment failure. |
|
|
Jose Bengoechea |
Infection biology of antibiotic resistant infections; developing new treatments based on host-directed approach |
|
|
Edel Hyland |
Targeting epigenetic/chromatin pathways to reverse antifungal resistance mechanisms in pathogenic fungi. |
|
|
Simon Cameron |
Detection, surveillance, AMR residues, diet- associated AMR |
|
|
Chris Creevey |
Profiling for AMR genes in microbiome datasets and genome. Development of novel machine learning approaches to link AMR genotype to phenotype. |
|
|
Beckie Ingram |
Host immune response, vaccine, in vivo preclinical models |
|
|
Garry Laverty |
Mainly antimicrobial drug delivery and biomaterials. Development of a long-acting drug delivery implant for combined HIV/AIDs and contraception using a hydrogel composed of peptides. Peptide hydrogels to target bacterial infections including biofilms. We have an interest in antimicrobial peptides and formulation of antimicrobial molecules. |
|
|
Miguel A. Valvano |
I work with highly MDR opportunistic pathogens (Burkholderia, Achromobacter and Enterobacter species). Focus is on polymyxin resistance, antibiotic mediated stress and heteroresistance. |
|
|
Cuong Cao |
Development of sensing technology for early detection of AMR pathogens |
|
|
Carmel Hughes |
Promoting better prescribing of antimicrobials in at risk populations through intervention studies |
|
|
Moira Dean |
Consumer and stakeholder perceptions, understanding, behaviour and behaviour change - social science |
|
|
Gerd Wagner |
Development of chemical tools and probes for bacterial profiling; design and development of new antimicrobials and diagnostics |
|
|
Séamus Fanning |
WGS-based sequencing to characterise AMR-expressing zoonotic (food-borne) pathogens. Short- and long-read shot-gun metagenomics to characterise resistomes in various ecological niches. Interest in mechanisms of bacterial resistance to disinfectants. |
|
|
Ben Collins |
Several collaborations where contribute from a technical perspective on AMR problems related to host-pathogen interactions and drug discovery. Main focus is on technical aspects of quantitative proteomics using mass spectrometry. |
|
|
Michael Tunney |
AMR in chronic respiratory infection: cystic fibrosis, bronchiectasis, COPD. Rapid detection and treatment of infection. |
|
|
Laura Sherrard |
Phenotypic and genotypic AMR characterisation in bacteria |
|
|
Julianne Megaw |
Environmental AMR, AMR in archaea |
|
|
Sharon Huws |
Livestock focussed AMR broadening out to One Health |
|
|
Thomas Thompson |
Mechanisms and tolerance towards antibiotics using bioinformatics |
|
|
Omololu Fagunwa |
The potential of a novel transdermal microneedle in prevention of antibiotics resistance |
|
|
Gisli G Einarsson |
Various aspects of AMR associated with infections in chronic respiratory diseases (CF, bronchiectasis, COPD) |
|
|
AJ McKnight |
Molecular focused |
|
|
Dimitrios Lamprou |
The manufacturing of different systems using electrospinning & 3D printing |
|
|
Colin McCoy |
Develop strategies to address colonisation of biomaterials and medical devices to resistant (and other) infections |
|
|
Matthew Wylie |
Development of antimicrobial surfaces and infection-responsive diagnostics and drug delivery systems |
|
|
James Burrows |
Research on bacterial proteases potentially involved |
|
|
Guillermo Lopez Campos |
Bioinformatics and computational biology in different microbiological aspects related with AMR |
|
|
Clare Mills |
Biomarkers of bacterial/viral infection in paediatrics |
|
|
Cecilia O'Kane |
Host directed therapies to combat infection |
|
|
Chris Watson |
Host response biomarkers to identify patients with bacterial infection. Clinical studies, biomarker discovery and validation. |
|
|
Fionnuala Lundy |
Investigating the efficacy of naturally occurring/novel synthetic peptides and peptide hydrogels against oral and respiratory pathogens |
|
|
Bronagh Elmore |
Investigating the potential role of a transmembrane peptidase in biofilm formation and antibiotic resistance. |
|
|
Simon Doherty |
Collaborative research, mainly re animal health but also AMR policy development |
|
|
Danielle Allen |
Hoping to start looking at bacterial and fungi resistance in the environmental samples (including wastewater and air sample). |
|
|
Lucy Dillon |
Bioinformatic approach, using machine learning to predict AMR phenotype using genomic data. |
|
|
Emmet Campbell |
Bacteriophage therapies targeted for Streptococcus suis as an alternative to antimicrobial use in pig farms across Ireland |
|
|
William O’Neill |
Wastewater struvite and compost |
|
|
Alberto Longo |
Economics of AMR |
|
|
Brian Green |
Identify novel, natural compounds which posses potent immunomodulatory activity. Improve a host's ability to counter an infections but without contributing to the development of AMR. Technology is being trialled in piglets with potential applications in poultry, aquaculture and companion animals, with a view to later use in humans. Our spin-out company Aramune is commercializing this technology. |
|
|
Tesleem Adewale Ibrahim |
Evaluation of plant based botanical as alternative to therapeutic antibiotics |
|
|
Angela Mousley |
Antimicrobial peptide (AMP) discovery and functional biology in helminths (flatworms and roundworms); AMP detection in helminth biofluids; worm microbiome; worm-microbe-host interactions |
|
|
Sian Cairns |
Investigation into the presence and origin of AMR microbes and AMR genes in infant formula milk products. |
|
|
Louise Atkinson |
Identification and functional characterisation of AMPs in helminth parasites |
|
|
Garba Mohammed Khalid |
Preparation and characterisation of drug loaded surgical sutures (with antimicrobial agents) for improved post-surgical wound care and management. |
|
|
Frances Benton |
Using honey as an anti-microbial agent against ESKAPE pathogens |
|
|
Katie Lawther |
AMR associated with agriculture and One Health. Main research focuses on AMR within ruminant microbiomes. |
|
|
Sreyashi Acharjee |
Anti-fungal drug Tolerance and resistance in pathogenic fungi C. glabrata |
|
|
Lynsey Patterson |
Secondary data analysis: Pharmaco- epidemiology - prescribing in primary / secondary care / care homes, surveillance and epidemiology of AMR in NI. Joint appointment between CPH and the Public Health Agency - previously lead for AMR surveillance and contributed to NI strategy for tackling AMR. |
|
|
Tim Skvortsov |
Phage research, metagenomics |
|
|
Timothy Geary |
Antiparasitic drug resistance; pharmacology and mechanisms |
|
|
Brett Greer |
I LC-MS/MS method for the analysis of > 130 AMRs including various classes of antibiotics, antiparasitics and anti- inflammatories. The method is validated for both milk and poultry feed and a workflow for the untargeted analysis of AMRs. |
|
|
Keren Turton |
Highly-drug-resistant opportunistic pathogen, Achromobacter. |
|
|
Gama Dominic |
Anti tuberculosis |
|
|
Yashkumar Vyas |
|
|
|
Madhvi Bhakta |
|
|
|
Rebekah Miskimmin |
Working on development of an anti fungal vaccine in an attempt to combat anti fungal resistance |
|
|
Katrina Campbell |
Diagnostics and detection of antibiotic residues |
|
|
Peter Alexander |
Discovery and development of novel antimicrobial compounds against ESKAPE pathogens |
|
|
Cliff Taggart |
Developing peptides with novel antibacterial activity to use against lung bacterial pathogens and possibly other pathogens |
|
|
Annette O Farrell |
Mass Spec identification of antibiotics in animal feed stuffs |
|
|
Ann Harkin |
Plant-derived antimicrobials (PDAMs) |
|
|
Holly McCormack |
Deriving novel antimicrobial peptides from parasitic livestock nematodes |
|
|
Izabella de Carvalho Batista Muniz |
Culturomics |
|
|
Gunnar Schroeder |
The molecular basis of infection by opportunistic intracellular bacterial pathogens, e.g. Legionella spp, M. avium to develop new host-directed therapies; and assays which also allow screening of new antibiotics in an infection context. |
|
|
Timothy Shaw |
Host-directed therapies for mycobacterial infections |
|
|
Marina Reyne |
Detecting AMR in the environment |
|
|
Peter Maduabuchi Eze |
Antimicrobial Drug Discovery/Bioprospecting |
|
|
Theano Stoikidou |
Culturomics with an interest in AMR, citizen science |
|
|
Amy Bryson |
Interested in vaccines to combat resistant microbes |
|
|
Darrin McKenzie |
Antimicrobial peptides in nematode biofluids |
|
|
Allister Irvine |
Characterisation of Antimicrobial Peptides from parasitic worms |
|
|
Louise Carson |
Anti-infective biomaterials to prevent medical device associated infection |
|
|
Connor Bamford |
Viruses and resistance to antivirals |
|
|
Stephen Cochrane |
Tools of organic synthesis, genetic engineering and molecular biology to study novel enzymatic processes, antimicrobial resistance mechanisms and the mechanism of action of antimicrobial and anticancer peptides |